Binds A Plasma Protein, Serum Protein, Or Fibrin (e.g., Clotting Factor Fibrinolytic Factor, Complement Factor, Immunoglobulin, Apolipoprotein, Etc.) Patents (Class 435/337)
-
Patent number: 7785898Abstract: The present invention provides methods for identifying and/or enriching fetal cells from maternal blood, using as fetal cell markers the antibodies that the mother produces against paternally inherited fetal antigens. The fetal cell-maternal antibody complexes are identified and isolated using labelled agents that bind to the maternal antibodies. The present invention also provides fetal cells, isolated by use of said maternal antibodies, as a source of fetal DNA for prenatal genetic diagnosis of the fetus.Type: GrantFiled: May 30, 2003Date of Patent: August 31, 2010Assignee: Genetic Technologies LimitedInventor: Ralph M. Bohmer
-
Patent number: 7771996Abstract: Variants of FVII or FVIIa comprising at least one amino acid modification in position 196, 237 or 341 relative to hFVII or hFVIIa. The variants exhibit an increased clotting activity, i.e. reduced clotting time, compared to rhFVIIa.Type: GrantFiled: March 22, 2004Date of Patent: August 10, 2010Assignee: Bayer Healthcare LLCInventors: Kim Vilbour Andersen, Mads Röpke, Jesper Mortensen Haaning, Steven Glazer
-
Patent number: 7728115Abstract: The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4/heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT/HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.Type: GrantFiled: August 2, 2005Date of Patent: June 1, 2010Assignee: STC. UNMInventors: Gowthami M. Arepally, Walter Kisiel, Keiko Kamei, Shintaro Kamei
-
Patent number: 7700085Abstract: The present invention provides a method for treating symptoms of diabetes in a diabetic subject which comprises administering to the subject a therapeutically effective amount of an agent which inhibits binding of advanced glycation endproducts to any receptor for advanced glycation endproducts so as to treat chronic symptoms of diabetes in the subject.Type: GrantFiled: May 20, 2004Date of Patent: April 20, 2010Assignee: The Trustees of Columbia University in the City of New YorkInventors: David M. Stern, Ann Marie Schmidt
-
Publication number: 20100009393Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.Type: ApplicationFiled: January 23, 2008Publication date: January 14, 2010Inventors: Bryan Paul Morgan, Claire Louisa Harris, Svellana Hakobyan
-
Patent number: 7566530Abstract: The invention relates to a method for detecting PrP in a biological human or animal sample that may contain PrP. The inventive method is characterised in that it uses a molecule containing at least one positive charge and/or at least one osidic bond and a ligand other than a proteinic ligand selected from macrocyclic ligands and glycosaminoglycanes.Type: GrantFiled: January 19, 2005Date of Patent: July 28, 2009Assignees: Biomerieux, Universite Claude Bernard Lyon, Centre National de la Recherche Scientifique, Agence Francaise de Securite Sanit Aire des AlimentsInventors: Anna Benscik-Reynier, Anthony William Coleman, Eric Da Silva, Marilyne Dupin, Edwige Leclere, Ambroise Martin, Aly Moussa, Herve Perron, Frederic Ronzon
-
Patent number: 7541160Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA method and kits for VEGF as an antigen were developed to detect VEGF levels in biological samples from animal models and human patients and are used as a diagnostic/prognostic index.Type: GrantFiled: November 1, 2004Date of Patent: June 2, 2009Inventors: David Tai Wai Fei, Kristen Tomita
-
Patent number: 7534580Abstract: In the serum, PSP94 occurs as a free form or is associated with a carrier protein. PSP94 in its bound form has been quantified in the blood of prostate cancer patients and these measurements have shown utility as evaluation or prognosis of prostate cancer. Diagnostic assays, methods, and kits for detecting a free form of PSP94, and reagents such as antibodies able to bind to a free form of PSP94 are disclosed herein.Type: GrantFiled: June 17, 2005Date of Patent: May 19, 2009Assignee: Ambrilia Biopharma Inc.Inventors: Jonathan Reeves, Edward Jerome Tanner, Chandra J. Panchal, Pierre Du Ruisseau
-
Publication number: 20090017040Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins.Type: ApplicationFiled: June 12, 2008Publication date: January 15, 2009Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Publication number: 20080206254Abstract: The present invention relates to new antibodies and fragments and derivatives thereof, which are particularly suited for the characterization of the structure and function of Factor VIII (FVIII) of the coagulation pathway, for the design of therapeutic strategies for eradication of FVIII inhibitors and for the use as a medicament The invention also relates to cell lines producing the specific antibodies. The present invention furthermore relates to pharmaceutical compositions comprising the antibodies, fragments and/or derivatives of the Invention and to methods of preventing and treating cardiovascular disorders by using the antibodies or fragments and derivatives thereof or pharmaceutical compositions thereof.Type: ApplicationFiled: July 31, 2006Publication date: August 28, 2008Applicant: Life Sciences Research Partners vzwInventors: Marc Jacquemin, Jean Guy Gilles, Jean-Marie Saint-Remy
-
Patent number: 7408027Abstract: The invention relates to epitopes of the tau protein which are specifically occurring in a phosphorylated state in tau protein from Alzheimer paired helical filaments, to protein kinases which are responsible for the phosphorylation of the amino acids of the tau protein giving rise to said epitopes, and to antibodies specific for said epitopes. The invention further relates to pharmaceutical compositions for the treatment or prevention of Alzheimer's disease, to diagnostic compositions and methods for the detection of Alzheimer's disease and to the use of said epitopes for the generation of antibodies specifically detecting Alzheimer tau protein. Additionally, the invention relates to methods for testing drugs effective in dissolving Alzheimer paired helical filaments or preventing the formation thereof.Type: GrantFiled: August 17, 2000Date of Patent: August 5, 2008Assignee: Max-Planck-Gesellschaft zur Forderung der WissenchaftenInventors: Eva-Maria Mandelkow, Eckhard Mandelkow, Birgit Lichtenberg-Kraag, Jacek Biernat, Gerard Drewes, Barbara Steiner
-
Patent number: 7291333Abstract: A method of inhibiting microvascular bleeding is provided. Antibody to protein C administered to a patient in a pharmaceutically acceptable carrier prevents anticoagulation by greater than 90% of activated protein C in human plasma.Type: GrantFiled: October 14, 1994Date of Patent: November 6, 2007Assignee: Oklahoma Medical Research FoundationInventor: Philip C. Comp
-
Patent number: 7273925Abstract: The invention relates to methods and products for regulating lectin complement pathway associated complement activation. The methods include both in vitro and in vivo methods for inhibiting lectin complement pathway associated complement activation. The methods are accomplished by contacting a mammalian cell having surface exposed MBL ligand with an effective amount of a mannan binding lectin inhibitor to inhibit lectin complement pathway associated complement activation. The mannan binding lectin inhibitor may be administered to a subject to prevent cellular injury mediated by lectin complement pathway associated complement activation. The products of the invention include compositions of a mannan binding lectin inhibitor. The mannan binding lectin inhibitor is an isolated mannan binding lectin binding peptide that selectively binds to a human mannan binding lectin epitope and that inhibits lectin complement pathway associated complement activation.Type: GrantFiled: December 15, 1999Date of Patent: September 25, 2007Assignee: Brigham and Women's Hospital, Inc.Inventors: Gregory L. Stahl, Charles D. Collard
-
Patent number: 7241578Abstract: The immunoassay method of this invention measures the content of a subject substance in a sample. The method includes the steps of: (a) preparing a mixed solution by mixing the sample and an antibody solution including a first monoclonal antibody and a second monoclonal antibody capable of specifically binding to the subject substance; and (b) measuring an optical property of the mixed solution. The first monoclonal antibody is capable of binding to a first epitope of the subject substance, and the second monoclonal antibody is capable of binding to a second epitope of the subject substance different from the first epitope. Each of the first and second epitopes exists singly in the subject substance.Type: GrantFiled: May 20, 2003Date of Patent: July 10, 2007Assignee: Matsushita Electric Industrial Co., Ltd.Inventors: Keiko Yugawa, Nobuyuki Shigetoh, Akihito Kamei, Tatsurou Kawamura
-
Patent number: 7183108Abstract: The invention concerns lactic acid bacteria strains capable of regulating the production of NO and inflammatory cytokines by enterocytes, depending on the inflammatory condition of said enterocytes. The strains can also be incorporated in food supplements such as fermented dairy products used for regulating inflammatory response and non-specific immunity.Type: GrantFiled: November 18, 1999Date of Patent: February 27, 2007Assignee: Compagnie Gervais DanoneInventors: Chantal Cayuela, Nathalie Dugas, Eric Postaire
-
Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
Patent number: 7022521Abstract: The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.Type: GrantFiled: June 24, 2003Date of Patent: April 4, 2006Assignee: Emory UniversityInventor: Stephen R. Hanson -
Patent number: 6998468Abstract: The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.Type: GrantFiled: March 23, 2001Date of Patent: February 14, 2006Assignee: Tanox, Inc.Inventors: Michael S. C. Fung, Cecily R. Y. Sun, William N. C. Sun
-
Patent number: 6989241Abstract: A highly specific monoclonal antibody, produced by a hybridoma cell has been found. A new assay, highly specific for activated protein C (APC) has been developed which will permit rapid determination of APC levels in clinical situations.Type: GrantFiled: October 2, 2001Date of Patent: January 24, 2006Assignee: Oklahoma Medical Research FoundationInventors: Charles T. Esmon, Patricia C. Y. Liaw, Gary L. Ferrell
-
Patent number: 6969516Abstract: A method is described comprising the combined administration of a novel composition comprising serum complement proteins with complement-fixing antibodies to induce transient disruption of myelin and/or demyelination. The antibodies specifically bind to one or more epitopes of myelin, and complement proteins. A method is also described for promoting regrowth, repair, and regeneration of neurons in a mammalian subject. The methods can be used following immediate or chronic injury.Type: GrantFiled: October 28, 1998Date of Patent: November 29, 2005Assignee: MBM & Co.Inventors: John D. Steeves, Jason K. Dyer, Hans S. Keirstead
-
Patent number: 6964854Abstract: The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4/heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT/HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.Type: GrantFiled: July 13, 2000Date of Patent: November 15, 2005Assignee: Science & Technology CorporationInventors: Gowthami M. Arepally, Walter Kisiel, Keiko Kamei, Shintaro Kamei
-
Patent number: 6960472Abstract: Monoclonal antibodies having high affinity for N-terminus pro brain natriuretic peptide (NT-proBNP) are described. The monoclonal antibodies are prepared against a synthetic peptide having the Sequence ID No. 1. Specifically, the monoclonal antibodies described are produced from two hybridoma cell lines, 6G11-F11-D12 and 1C3-E11-R9, deposited with the American Type Culture Collection under Accession Numbers PTA-4844 and PTA-4845 respectively. The monoclonal antibody antibodies can be used as reagents in an immunoassay system to identify blood, serum or plasma levels of NT-proBNP. Such an immunoassay system can be used for diagnosing and quantifying congestive heart failure (CHF).Type: GrantFiled: February 4, 2003Date of Patent: November 1, 2005Assignee: Ottawa Heart Institute Research CorporationInventor: Adolfo J. DeBold
-
Patent number: 6956107Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: March 29, 2001Date of Patent: October 18, 2005Assignee: Tanox, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 6911178Abstract: Disclosed are novel protein and peptide compositions comprising soluble and bound forms of immunologically-active blood group antigens including mammalian Rh antigens. In preferred embodiments methods for the isolation and purification of serologically-active human Rh antigens such as D, c, C, E, and e are disclosed. Also disclosed are methods for the adsorption of immunologically-active Rh antigens to solid supports. Diagnostic kits, methods, and devices for the detection of Rh antibodies in clinical and non-clinical samples are also disclosed. Devices, compositions and methods for the isolation, purification and quantitation of anti-Rh antibodies from solution are also provided.Type: GrantFiled: November 14, 2001Date of Patent: June 28, 2005Assignees: Board of Regents, The University of Texas System, Baylor College of MedicineInventors: L. Scott Rodkey, Marwan A. Yared, Kenneth J. Moise, Jr.
-
Patent number: 6893831Abstract: The present invention provides an immunoassay for specifically measuring with high sensitivity PIVKA-II in serum or plasma through antigen-antibody reaction by adding an animal serum containing thrombin and/or an antibody reacting with human fibrin-like related substances to the reagents. The immunoassay of the invention comprises the steps of adding thrombin and/or an antibody reacting with human fibrin-like related substances to the reagents, and measuring PIVKA-II in serum or plasma.Type: GrantFiled: June 1, 2000Date of Patent: May 17, 2005Assignee: Sanko Junyaku Co., Ltd.Inventors: Motohito Kanashima, Tomohide Asai, Hiroki Takahashi, Yoshiyuki Asai
-
Patent number: 6855508Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA method and kits for VEGF as an antigen were developed to detect VEGF levels in biological samples from animal models and human patients and are used as a diagnostic/prognostic index.Type: GrantFiled: August 5, 2002Date of Patent: February 15, 2005Assignee: Genentech, Inc.Inventors: David Tai Wai Fei, Kristen Tomita
-
Patent number: 6838250Abstract: The present invention relates to new CRP immunoassay compositions. The compositions include a low affinity anti-human CRP monoclonal antibody, and an antiidiotypic antibody raised against it. The invention further provides a method for obtaining antiidiotypic monoclonal antibody populations directed to an antibody that is specific for a high concentration, high molecular weight target antigen.Type: GrantFiled: March 29, 2001Date of Patent: January 4, 2005Assignee: Ortho-Clinical Diagnostics, Inc.Inventors: Edward R. Scalice, John L. Daiss
-
Patent number: 6830896Abstract: The present invention provides a process and regent for analyzing annexin-V, wherein the measurement of a concentration of annexin-V can be easily carried out without need for addition of chemicals for inhibiting the bonding of various proteins with calcium ion and for adjusting a specimen solution to the specimen at a measuring stage, and a process and medicine for diagnosing an internal organ disorder based on the analyzing process and regent. A urine is brought into contact with an anti-annexin-V monoclonal antibody to perform an antigen-antibody reaction of annexin-V in the urine with the anti-annexin-V monoclonal antibody, thereby forming an annexin-V antigen/anti-annexin-V monoclonal antibody complex, and the amount of the formed annexin-V antigen/anti-annexin-V monoclonal antibody complex is quantitatively measured.Type: GrantFiled: November 15, 2002Date of Patent: December 14, 2004Inventors: Noboru Kaneko, Ryuko Matsuda, Tadahiro Kajita
-
Patent number: 6793920Abstract: A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.Type: GrantFiled: August 8, 2001Date of Patent: September 21, 2004Assignee: Ajinomoto Co., Inc.Inventors: Mitsuyo Nagano, Hiroshi Yamamoto, Morikazu Kito, Ryota Yoshimoto, Tsuyoshi Kobayashi
-
Publication number: 20040109858Abstract: The present invention is directed to antibodies and antibody fragments that bind specifically to the active conformation of human von Willebrand factor. Most preferred are recombinantly produced single chain variable immunoglobulin fragments. Because the antibodies or antibody fragments act only at the sites of thrombus formation and do not interfere with the normal activity of circulating platelets, they are particularly well suited for use as antithrombotic agents in a wide variety of applications.Type: ApplicationFiled: June 20, 2003Publication date: June 10, 2004Applicant: Brigham and Women's Hospital, Inc.Inventors: Robert I. Handin, Huabing Yuan, Anne McLeod
-
Patent number: 6733980Abstract: Diagnostic methods comprise measuring specifically the level of at least one iso-eosinophilic cationic protein (iso-ECP) in a sample from an individual to be diagnosed, and comparing the measured level of the iso-ECP with a predetermined level of the iso-ECP. The iso-ECP is cytotoxic and the cytotoxicity of the iso-ECP is not capable of neutralization by the monoclonal antibodies EG1 and EG2. Anti-iso-ECP antibody which may be used in the diagnostic methods specifically binds to a cytotoxic isoform of ECP having an epitope which is unique for the native form of the cytotoxic iso-ECP.Type: GrantFiled: December 1, 1998Date of Patent: May 11, 2004Assignee: Pharmacia Diagnostics ABInventors: Per Venge, Christer Peterson
-
Publication number: 20030215447Abstract: A monoclonal antibody which inhibits the blood clotting factor VII-activating protease and its proenzyme and a blood clotting factor VII-activating protease, stabilized by the addition of said monoclonal antibody, and its proenzyme are described. A suitable monoclonal antibody is produced by hybridoma cell line DSM ACC 2533. The application of the inhibitory, monoclonal antibody in the stabilization of blood clotting preparations and in preparations for reducing the coagulability of the blood is disclosed.Type: ApplicationFiled: February 7, 2003Publication date: November 20, 2003Inventors: Juergen Roemisch, Wiegand Lang, Annette Feussner, Gudrun Muth-Naumann, Hans-Arnold Stoehr, Christian Kannemaier, Klaus Preissner, Fumie Nakazawa
-
Publication number: 20030211102Abstract: The present invention relates to prophylactic and therapeutic methods of immunization against neoplastic and infectious diseases. The invention provides a method for identification of novel immunogens and compositions of such immunogens that are useful for eliciting immune responses against antigens associated with neoplastic or infectious diseases.Type: ApplicationFiled: March 3, 2003Publication date: November 13, 2003Inventor: Raj Tiwari
-
Publication number: 20030103975Abstract: A novel laminin complex is described composed of subunits of &agr;4, &bgr;3, and &ggr;1 laminins. Further described is a fragment of &agr;4 laminin which binds integrin, and agents capable of modulating the binding of &agr;4 laminin to the &agr;v&bgr;3 integrin receptor. Therapeutic methods are disclosed for inhibiting tumor growth by inhibiting neovascularization. Also, screening methods are disclosed for identifying agents capable of modulating angiogenesis by modulating the binding of &agr;4 laminin to the &agr;v&bgr;3 integrin receptor.Type: ApplicationFiled: November 18, 2002Publication date: June 5, 2003Inventors: Jonathan C.R. Jones, Meredith Gonzales
-
Patent number: 6544786Abstract: A method for trans-splicing peptides is provided. In the method, at least two extein peptides are provided, or are synthesized by recombinant methods, the extein peptides having co-reacting portions of a split intein attached thereto, so that the peptides will splice automatically under suitable conditions. A vector is also provided which includes at least one extein gene for expressing at least one of the extein peptides. Further provided is a method for circumventing packaging limitations in a gene delivery vehicle, by splitting a coding region for a protein to be delivered into two or more extein genes, which are packaged in separate virus particles and are co-delivered to a target cell for expression and for subsequent trans-splicing to form the complete protein. A pharmaceutical composition and a therapeutic method are also provided in which the recombinant viral particles are delivered to a cell and are expressed to produce a trans-spliced protein.Type: GrantFiled: October 13, 2000Date of Patent: April 8, 2003Assignee: University of Pittsburgh of the Commonwealth of Higher EducationInventors: Xiao Xiao, Paul Xiangoin Liu
-
Patent number: 6534058Abstract: The invention relates to C5 inhibitors, which inhibit type II endothelial cell activation, wherein the inhibition is manifested by the suppression of E-selectin. These inhibitors are useful in treatment of delayed xenograft rejection or acute vascular rejection. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. Examples of monoclonal antibodies, which bind to and inhibit C5, were generated and are designated MAb 137-76 and MAb 137-30.Type: GrantFiled: October 4, 2001Date of Patent: March 18, 2003Assignee: Tanox, Inc.Inventors: Michael S. C. Fung, Bill N. C. Sun, Cecily R. Y. Sun
-
Patent number: 6524862Abstract: A selective complex of a lipoprotein with hemoglobin or a hemoglobin analogue. A method of assaying hemoglobin or a hemoglobin analogue in a sample, comprising reacting the sample with a lipoprotein which is capable of selectively forming a complex with hemoglobin or a hemoglobin analogue. A kit for assaying hemoglobin or a hemoglobin analogue, comprising a lipoprotein which is capable of selectively forming a complex with hemoglobin or a hemoglobin analogue.Type: GrantFiled: June 8, 2001Date of Patent: February 25, 2003Assignee: Arkray, Inc.Inventors: Masashi Okamoto, Hajime Nakano
-
Patent number: 6485970Abstract: The present invention relates generally to immunointeractive molecules and their use inter alia in the detection and/or purification of T-cell antigen binding molecules (TABMs). The ability to determine the presence and levels of particular TABMs provides a useful diagnostic procedures for a variety of disease conditions.Type: GrantFiled: May 10, 2000Date of Patent: November 26, 2002Inventors: Robert E. Cone, George M. Georgiou, Colin H. Little
-
Publication number: 20020160508Abstract: In accordance with the present invention a novel fibrin polymer structure is disclosed. The novel fibrin polymer structure useful, for example, as a surgical sealant, is comprised of a plurality of discrete, droplets of polymerizing or polymerized fibrin each encapsulated by a “skin” of fibrin polymer. These fibrin-skin encapsulated droplets are applied so as to be built up one upon the other, layer by layer, to form an integral sealant structure. The cumulative effect of the encapsulating skins of those droplets which form the sealant surface is a surface skin which unexpectedly resists cell penetration but enhances cell migration across the surface. The sealant structure of the present invention can be prepared by spray delivery of fibrin polymer forming materials wherein the time required for the materials to commence polymerizing after mixing is less than or equal to the transit time of said materials from the applicator tip to the target surface.Type: ApplicationFiled: November 29, 2001Publication date: October 31, 2002Inventors: Stewart A. Cederholm-Williams, Julian M. Marshall, Jose L. Velada, Derek A. Hollingsbee
-
Patent number: 6451545Abstract: Provided are a monoclonal antibody making it possible to detect a native fibrin monomer, which is produced at the initial state of blood coagulation, and soluble fibrin; a hybridoma; and an immunoassay for detecting the initial stage of blood coagulation with high sensitivity, quickly, using the monoclonal antibody. Using a fibrinogen analog in blood as an immune source, cell fusion is carried out to prepare a monoclonal antibody which is not reactive with fibrinogen and is specifically and simultaneously reactive with a native fibrin monomer (that is, a fibrin monomer which is present in a body fluid, in particular in blood, and is not solubilized) and soluble fibrin. The fibrin monomer analog is preferably fibrinogen treated with bathroxobin, which is a snake venom.Type: GrantFiled: February 17, 1999Date of Patent: September 17, 2002Assignee: Nissui Pharmaceutical Co., Ltd.Inventors: Seiji Tanaka, Akiei Hamano, Mamoru Umeda
-
Patent number: 6451599Abstract: The invention provides monoclonal antibodies which are reactive with fibrin(ogen) degradation products (FDPS) generated by matrix metalloproteinases (MMPs), such as MMP-3, MMP-7, and membrane-type 1, MT1-MMP proteolysis of fibrinogen and cross-linked fibrin (and not plasmin or other proteases). Monoclonal antibodies of the invention include, but are not limited to, H5, F2, 90/2, 90/5, B4, 13, C6, A6, G6, E6, 197-1 and 197-2. This invention also provides methods of using monoclonal antibodies for detection of FDPs generated by proteolysis of fibrin(ogen) by MMPs, such as MMP-3, MMP-7, and MT1-MMP. In addition, the present invention provides methods for diagnosing rheumatoid arthritis, osteoarthritis, and synovitides, as well as angiogenesis, atherosclerosis, renal diseases, malignancy and inflammation.Type: GrantFiled: April 13, 2000Date of Patent: September 17, 2002Assignee: New York Blood CenterInventors: Alessandra Bini, Bohdan J. Kudryk
-
Patent number: 6391568Abstract: The present invention provides a method for the quantification and assessment of platelet activation in whole blood samples and monitoring of antiplatelet pharmacologic agents. The method for quantifying platelet activation includes exposing platelets to a physiological concentration of an agonist that activates some of the platelets, resulting in the formation of at least one binding site on the surface of the activated platelets, and measuring the activated platelets. The present invention provides a method of assessing specific components of platelet activation.Type: GrantFiled: July 15, 1998Date of Patent: May 21, 2002Assignee: Lionheart Technologies, Inc.Inventors: David J. Schneider, Burton E. Sobel, Paula B. Tracy, Paul G. Held, Paul D. Hale, Norman R. Alpert
-
Patent number: 6391635Abstract: Disclosed herein are method for producing hydridoma cell lines producing monoclonal human natural IgM antibodies and hybridoma cells produced by the methods. The antibodies are the monoclonal equivalents of circulating human natural antibodies.Type: GrantFiled: May 23, 2000Date of Patent: May 21, 2002Assignee: Institute for Human Genetics and BiochemistryInventor: Toby C. Rodman
-
Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
Patent number: 6376242Abstract: The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.Type: GrantFiled: September 21, 2000Date of Patent: April 23, 2002Assignee: Emory UniversityInventor: Stephen R. Hanson -
Patent number: 6365155Abstract: Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof are used in pharmaceutical preparations and in diagnosis. Cells which express these antibodies, antibody fragments, mixtures or derivatives thereof are also disclosed.Type: GrantFiled: December 30, 1999Date of Patent: April 2, 2002Assignee: Abbott LaboratoriesInventors: Thomas Subkowski, Wilfried Hornberger
-
Patent number: 6355245Abstract: The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.Type: GrantFiled: June 7, 1995Date of Patent: March 12, 2002Assignee: Alexion Pharmaceuticals, Inc.Inventors: Mark J. Evans, Louis A. Matis, Eileen Elliott Mueller, Steven H. Nye, Scott Rollins, Russell P. Rother, Jeremy P. Springhorn, Stephen P. Squinto, Thomas C. Thomas, James A. Wilkins
-
Publication number: 20020028204Abstract: A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.Type: ApplicationFiled: August 8, 2001Publication date: March 7, 2002Applicant: Ajinomoto Co., Inc.Inventors: Mitsuyo Nagano, Hiroshi Yamamoto, Morikazu Kito, Ryota Yoshimoto, Tsuyoshi Kobayashi
-
Patent number: 6306653Abstract: An isolated chemokine is disclosed. The isolated chemokine is expressed preferentially in breast tissue or can be detected in breast milk. It includes from about 100 to about 132 amino acids, has a deduced molecular weight of from about 10 to about 16 kDa, and has a deduced isoionic point of from about pH 10.1 to about pH 10.7. Antibodies and binding portions thereof recognizing the subject chemokine and peptides which include the antigenic portions of the subject chemokines are described. DNA molecules which encode the subject chemokines as well as nucleic acid molecules which, under stringent conditions, hybridize to nucleic acid molecules encoding the subject chemokines or to a complement thereof are also disclosed.Type: GrantFiled: September 3, 1998Date of Patent: October 23, 2001Assignee: Codon Diagnostics, LLCInventors: Lawrence D. Papsidero, Lyn M. Dyster, Jana M. Frustaci
-
Patent number: 6280731Abstract: A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.Type: GrantFiled: April 26, 1999Date of Patent: August 28, 2001Assignee: Ajinomoto Co., Inc.Inventors: Mitsuyo Nagano, Hiroshi Yamamoto, Morikazu Kito, Ryota Yoshimoto, Tsuyoshi Kobayashi
-
Patent number: 6248546Abstract: A method of assaying the growth hormone status of an individual by immuno-assay for the 150 KDa Insulin-like Growth Factor ternary complex (IGF/IGFBP-3/ALS). Alternatively, a binary complex may be assayed. The method involves capturing the IGFBP complex with a first antibody coupled to a solid phase and detecting the complex with a second antibody coupled to a label. A set of monoclonal and polyclonal antibodies usefutl for the assay is also provided.Type: GrantFiled: March 9, 1998Date of Patent: June 19, 2001Assignee: Diagnostic Systems Laboratories, Inc.Inventors: M. Javad Khosravi, Anastasia Diamandi, Jehangir Mistry
-
Patent number: 6228360Abstract: Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.Type: GrantFiled: August 19, 1998Date of Patent: May 8, 2001Assignee: Ajinomoto Co., Inc.Inventors: Man Sung Co, Maximiliano Vasquez